Brief: Elicera Therapeutics Q2 Operating Loss Widens To SEK 4.5 Mln
Aug 29 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* Q2 OPERATING LOSS TOTALED SEK -4,466,286 (-3,641,800)
Source text for Eikon: ID:nWkrbjPkg5
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application